These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16447748)

  • 21. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses.
    Chackerian B; Rangel M; Hunter Z; Peabody DS
    Vaccine; 2006 Sep; 24(37-39):6321-31. PubMed ID: 16806604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for Alzheimer's disease.
    McGeer PL; McGeer E
    Sci Aging Knowledge Environ; 2004 Jul; 2004(27):pe29. PubMed ID: 15243154
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
    Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
    Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.
    Nicoll JA; Wilkinson D; Holmes C; Steart P; Markham H; Weller RO
    Nat Med; 2003 Apr; 9(4):448-52. PubMed ID: 12640446
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific humoral immune responses in rhesus monkeys vaccinated with the Alzheimer's disease-associated beta-amyloid 1-15 peptide vaccine.
    Li SB; Wang HQ; Lin X; Xu J; Xie Y; Yuan QF; Yao ZB
    Chin Med J (Engl); 2005 Apr; 118(8):660-4. PubMed ID: 15899121
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease.
    Kim HD; Maxwell JA; Kong FK; Tang DC; Fukuchi K
    Biochem Biophys Res Commun; 2005 Oct; 336(1):84-92. PubMed ID: 16126169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hopes remain for an Alzheimer's vaccine.
    Schenk D
    Nature; 2004 Sep; 431(7007):398. PubMed ID: 15385984
    [No Abstract]   [Full Text] [Related]  

  • 28. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
    Vasilevko V; Cribbs DH
    Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice.
    Bach P; Tschäpe JA; Kopietz F; Braun G; Baade JK; Wiederhold KH; Staufenbiel M; Prinz M; Deller T; Kalinke U; Buchholz CJ; Müller UC
    J Immunol; 2009 Jun; 182(12):7613-24. PubMed ID: 19494285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prophylactic and therapeutic vaccines against Alzheimer's disease].
    Zhang Z; Ma QJ
    Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):641-5. PubMed ID: 15971572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amyloid-beta immunotherapies in mice and men.
    Brendza RP; Holtzman DM
    Alzheimer Dis Assoc Disord; 2006; 20(2):118-23. PubMed ID: 16772748
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.
    Pride M; Seubert P; Grundman M; Hagen M; Eldridge J; Black RS
    Neurodegener Dis; 2008; 5(3-4):194-6. PubMed ID: 18322388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abeta species removal after abeta42 immunization.
    Nicoll JA; Barton E; Boche D; Neal JW; Ferrer I; Thompson P; Vlachouli C; Wilkinson D; Bayer A; Games D; Seubert P; Schenk D; Holmes C
    J Neuropathol Exp Neurol; 2006 Nov; 65(11):1040-8. PubMed ID: 17086100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current progress in beta-amyloid immunotherapy.
    Schenk D; Hagen M; Seubert P
    Curr Opin Immunol; 2004 Oct; 16(5):599-606. PubMed ID: 15342006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-mediated immunotherapy for Alzheimer's disease.
    Solomon B
    Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates.
    Gandy S; Walker L
    Curr Opin Immunol; 2004 Oct; 16(5):607-15. PubMed ID: 15342007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?
    Foster JK; Verdile G; Bates KA; Martins RN
    Mol Psychiatry; 2009 Mar; 14(3):239-51. PubMed ID: 18957942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amyloid beta-HSP60 peptide conjugate vaccine treats a mouse model of Alzheimer's disease.
    Nemirovsky A; Fisher Y; Baron R; Cohen IR; Monsonego A
    Vaccine; 2011 May; 29(23):4043-50. PubMed ID: 21473952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regression stage senile plaques in the natural course of Alzheimer's disease.
    Oide T; Kinoshita T; Arima K
    Neuropathol Appl Neurobiol; 2006 Oct; 32(5):539-56. PubMed ID: 16972888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls.
    Xu W; Kawarabayashi T; Matsubara E; Deguchi K; Murakami T; Harigaya Y; Ikeda M; Amari M; Kuwano R; Abe K; Shoji M
    Brain Res; 2008 Jul; 1219():169-79. PubMed ID: 18534566
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.